Introduction of SLC6A2
SLC6A2 is encoded by SLC6A2 gene. It belongs to the solute carrier family 6 which has been extensively studied during the past few decades because it offers numerous possibilities for therapeutic applications. It is a norepinephrine transporter which can remove norepinephrine into presynaptic nerve terminals, and is responsible for regulating norepinephrine homeostasis. Meanwhile, many studies conducted on SLC6A2 show that it is related to various diseases, such as orthostatic intolerance and syncope.
|Basic Information of SLC6A2|
|Protein Name||Sodium-dependent noradrenaline transporter|
|Organism||Homo sapiens (Human)|
Function of SLC6A2 Membrane Protein
SLC6A2, also named as norepinephrine transporter (NET), is mainly expressed in adrenal, placenta and testis. It can exert spatial and temporal control over the action of norepinephrine. The NET mediates the termination of neurotransmission via the reuptake of norepinephrine released into the extracellular milieu. Recent studies indicate that SLC6A2 variants are strongly associated with orthostatic intolerance. In addition, researches have confirmed several SLC6A2 SNPs could be potential therapeutic targets for psychiatric disorders, postural tachycardia, and play an important role in attention-deficit/hyperactivity disorder risk.
Fig.1 SLC6A2 mutations in myoclonic astatic epilepsy. (Jedlitschky, 2012)
Application of SLC6A2 Membrane Protein in Literature
This article reports the association between the SLC6A2, SLC6A3, DRD2 polymorphisms and schizophrenia. These results indicate that no relationship is found in these three genes and schizophrenia in Han Chinese.
This article analyzes the influence of SLC6A2 SNPs on myocardial 123I-mIBG parameters in CHF. The data demonstrate that SLC6A2 gene polymorphism is not associated with any 123I-mIBG derived parameters in this specific CHF population.
Authors in this group analyze the expression and methylation levels of SLC6A2 in heart failure patients and examine the relationship between SLC6A2 and qi deficiency/blood stasis syndrome (QDS/BSS). The data show that the promoter abnormally methylation of SLC6A2 gene is one of the risk factors for HF and is related with QDS/BSS.
This article focuses on the association between SLC6A2 gene polymorphisms and remission after venlafaxine treatment for major depressive disorder. The results suggest that SLC6A2 variants are strongly associated with treatment remission after venlafaxine in patients with MMD.
This article conducts a case-control study to examine the expression of SLC6A2 and the gene polymorphisms in patients who suffer from posttraumatic stress disorder. The data illustrate that the rs2242446 polymorphism of SLC6A2 gene has no effect on PTSD.
SLC6A2 Preparation Options
To obtain the soluble and functional target protein, the versatile Magic™ membrane protein production platform in Creative Biolabs enables many flexible options, from which you can always find a better match for your particular project. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-SLC6A2 antibody development services.
As a forward-looking research institute as well as a leading custom service provider in the field of membrane protein, Creative Biolabs has won good reputation among our worldwide customers for successfully accomplishing numerous challenging projects including generation of many functional membrane proteins. Please feel free to contact us for more information.